An analyst earlier this month took aim at what’s behind a big run-up in shares of Irvine medical device maker Edwards Lifesciences Corp.: a new type of heart valve that doesn’t require major surgery.

One of Edwards Lifesciences Corp.’s major projects,developing a heart valve that doesn’t require major surgery,is moving along and gaining notice among analysts. Irvine-based Edwards recently started ...

CHICAGO, March 26 (Reuters) - Elderly patients who received a replacement heart valve through Edwards LifeSciences Corp's less-invasive technique had similar death rates and risk of stroke at two ...

CHICAGO (Reuters) - Edwards Lifesciences Corp said a U.S. regulatory advisory panel will review on July 20 its application to sell a replacement heart valve that spares patients the need for ...

Edwards Lifesciences (NYSE:EW) develops medical devices for structural heart disease, transcatheter procedures, and critical care, highlighting operational performance in the NYSE Composite sector.

The heart valve specialist reported a second straight quarter of double-digit TAVR sales growth and credited recent study results with driving a “sense of urgency” for treating patients.

Edwards Lifesciences has secured European approval for its transcatheter tricuspid valve replacement system, which the company described as the first minimally invasive therapy of its kind to receive ...

NEWBURY, England--(BUSINESS WIRE)--Edwards Lifesciences announced new data from the COMMENCE aortic trial, demonstrating low rates of structural valve deterioration (SVD) in bioprosthetic aortic ...

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of ...

Edwards Lifesciences has claimed the FDA’s first approval of a transcatheter replacement implant for a leaky tricuspid heart valve, three months after garnering a green light in Europe. The Evoque, ...